ADMA Biologics (NASDAQ: ADMA) — Company Overview, News & Financial Data
ADMA Biologics develops plasma-derived therapies for infectious diseases, focusing on improving outcomes for immune-compromised patients.
ADMA Biologics
ADMA Biologics (NASDAQ:ADMA) is a biopharmaceutical company deeply engaged in the development, manufacturing, and marketing of plasma-derived products for the treatment and prevention of infectious diseases. Their operations focus primarily on immune globulins, a class of medicines vital for people with weakened immune systems. A key aspect of their mission is to improve patient outcomes in immune-compromised and other patient populations across the globe. Through dedicated research and strategic collaborations, ADMA Biologics aims to expand its product portfolio, ensuring access to life-saving therapies for individuals in need. Their objectives center around advancing the quality and safety of plasma-derived therapies, increasing their market presence, and playing a pivotal role in the fight against infectious diseases by bringing innovative solutions to the healthcare sector.
Snapshot
Operations
Products and/or services of ADMA Biologics
- BIVIGAM, an IVIG product for treating patients with primary humoral immunodeficiency.
- ASCENIV, an IVIG immune globulin for immune compromised patients.
- Nabi-HB, a hepatitis B immune globulin for acute exposure to hepatitis B.
- Plasma collection centers, operational facilities for collecting and processing plasma.
- Respiratory syncytial virus (RSV) immune globulin, a specialized treatment for RSV.
- Contract manufacturing services, offering plasma fractionation and purification.
ADMA Biologics executive team
- Adam S. GrossmanCo-Founder, President, CEO & Director
- Jerrold B. GrossmanCo-Founder & Vice Chairman of the Board
- P. Terence KohlerCFO & Treasurer
- Kaitlin M. KestenbergCOO & Senior VP of Compliance
- Michael GoldsteinGeneral Counsel
- John HaflExecutive Director of Sales
- Skyler BloomSenior Director of Business Development & Corporate Strategy
Latest news about ADMA Biologics
Key financials
Reported results for ADMA Biologics, in USD.
- Market cap
- 2.5B
- Revenue (TTM)
- 512.3M
- P/E ratio
- 15.8
- EPS (diluted, TTM)
- 0.7
- Dividend yield
- —
- Profit margin
- 33.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 510.2M | 191.4M | 146.9M | |
| 426.5M | 139M | 197.7M | |
| 258.2M | 21.6M | -28.2M | |
| 154.1M | -39.4M | -65.9M |